Lisa Haddad is a partner in the firm’s Public M&A / Corporate Governance practice. She focuses on mergers and acquisitions involving public companies and corporate governance matters. Lisa serves on the firm’s Allocations Committee. She was formerly a member of the firm’s Executive Committee, co-chair of the Public M&A / Corporate Governance practice, and co-chair of Goodwin’s Women’s Initiative.
Lisa has extensive experience in representing buyers, sellers and financial advisors in merger and acquisition transactions involving both public and private companies, especially in the life sciences and technology sectors. In this area, she has a special focus on public company mergers and acquisitions, spin-offs, and other complex transactions involving public companies.
Representative Matters
- Deciphera Pharmaceuticals in its $2.4 billion sale to Ono Pharmaceutical Co.
- Harpoon Therapeutics in its $700 million sale to Merck
- 2seventy bio in the divestiture of its oncology and autoimmune pipeline to Regeneron
- EQRx in its $1.1 billion sale to Revolution Medicines
- Forma Therapeutics in its $1.1 billion sale to Novo Nordisk
- Trillium Therapeutics in its $2.3 billion sale to Pfizer
- MyoKardia in its $13.1 billion sale to Bristol Myers Squibb
- bluebird bio in the spin-off of its oncology programs and portfolio into 2seventy bio
- Special Committee of NantKwest in NantKwest’s merger with ImmunityBio
- Spark Therapeutics in its $4.4 billion sale to Roche
- Centerbridge Partners in its $1.4 billion acquisition of Civitas Solutions
- Ipsen in its $1.3 billion (upfront cash and CVR) acquisition of Clementia Pharmaceuticals
- Foundation Medicine in its $1.0 billion sale of a majority stake to Roche and subsequent $2.4 billion negotiated tender offer for the public minority interest by Roche
- Teva Pharmaceutical in its $3.2 billion acquisition of Auspex Pharmaceuticals
- Teva Pharmaceutical in the sale of its animal health division to Bayer
- Haemonetics Corporation in its acquisition of Pall Corporation's blood collection, filtration and processing product lines
- Ansys in its pending $35.0 billion sale to Synopsys
- Ritchie Bros. Auctioneers in its $7.3 billion acquisition of IAA
- Citrix Systems in its $16.5 billion sale to Vista Equity Partners and Evergreen Coast Capital
- Mimecast in its $5.8 billion sale to Permira
- PTC in connection with a strategic partnership and $1.0 billion investment by Rockwell Automation
- Neustar in its $2.9 billion sale to Golden Gate Capital
- Cornerstone OnDemand in connection with a $300 million strategic investment led by Silver Lake
- Citrix Systems in a $2.9 billion Reverse Morris Trust transaction involving the merger of a division of Citrix with LogMeIn
- LoJack Corporation in its $135 million sale to CalAmp Corp.
- Trulia in its $3.5 billion sale to Zillow
- Eloqua in its $1.0 billion sale to Oracle
- Citrix Systems in its cooperation agreement with Elliott Management
- Cognex Corporation in the sale of its surface inspection systems division to AMETEK
- First Eagle Investment Management in its $500 million (upfront cash and CVR) acquisition of NewStar Financial
Professional Activities
Credentials
Education
JD1996
Harvard Law School
(magna cum laude)
BBA1993
University of Massachusetts Amherst
(cum laude)
Admissions
Bars
- Massachusetts
Recognition & Awards
Lisa has been recognized by:
- Chambers USA 2021-2024 for her work in Corporate/M&A
- The American Lawyer as a 2023 Dealmaker of the Year (along with Stuart Cable)
- The Best Lawyers in America for 2023
- The Deal’s Top Women in Dealmaking for 2022
- The American Lawyer as a 2022 Northeast Trailblazer
- BTI Consulting Group as a 2022 BTI Client Service All-Star
- The Legal 500 as a 2021 recommended lawyer for Corporate Governance and Shareholder Activism: Advice to Boards
Lisa also was recognized by the Financial Times with its award for Innovative Deal of the Year in 2015 for advising Foundation Medicine in its $1.0 billion majority purchase by Roche, and in 2016 for advising Citrix Systems in its $2.9 billion Reverse Morris Trust transaction with LogMeIn.
Publications
Lisa is a co-director of Goodwin’s Annual Directors Forum, an educational program designed for directors of public companies, and GOOD Directors, a leadership program focused on accelerating diversity in the boardroom. She also speaks at various board education programs and legal seminars on topics in her areas of practice.